Improving your health since 2000
Calcium channel blocking agents Group IV antiarrhythmics
Treating high blood pressure. It may be used alone or with other medicines. It may also be used for other conditions as determined by your doctor.
Verapamil sustained-release capsules controlled onset is a calcium channel blocker. It works by relaxing (dilating) your blood vessels, which lowers blood pressure.
Contact your doctor or health care provider right away if any of these apply to you.
Some medical conditions may interact with verapamil sustained-release capsules controlled onset. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
Some MEDICINES MAY INTERACT with verapamil sustained-release capsules controlled onset. Tell your health care provider if you are taking any other medicines, especially any of the following:
This may not be a complete list of all interactions that may occur. Ask your health care provider if verapamil sustained-release capsules controlled onset may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Use verapamil sustained-release capsules controlled onset as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use verapamil sustained-release capsules controlled onset.
All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:
Seek medical attention right away if any of these SEVERE side effects occur:
Constipation; dizziness; fatigue; headache; lightheadedness; nausea.
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; fainting; lightheadedness, especially when standing; severe dizziness; shortness of breath; swelling of the feet or hands; symptoms of liver problems (eg, yellowing of the skin or eyes, dark urine, pale stools, severe or persistent stomach pain, fever, general feeling of being unwell); unusually fast, slow, or irregular heartbeat.
This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include decreased mental status; dizziness; loss of consciousness; shortness of breath; slow or irregular heartbeat.Proper storage of verapamil sustained-release capsules controlled onset:
Store verapamil sustained-release capsules controlled onset at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep verapamil sustained-release capsules controlled onset out of the reach of children and away from pets.
This information should not be used to decide whether or not to take verapamil sustained-release capsules controlled onset or any other medicine. Only your health care provider has the knowledge and training to decide which medicines are right for you. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about verapamil sustained-release capsules controlled onset. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to verapamil sustained-release capsules controlled onset. This information is not specific medical advice and does not replace information you receive from your health care provider. You must talk with your healthcare provider for complete information about the risks and benefits of using verapamil sustained-release capsules controlled onset.
Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only your health care provider has the knowledge and training to decide which medicines are right for you. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from your health care provider. You must talk with your healthcare provider for complete information about the risks and benefits of using this medicine.
It is possible that some side effects of verapamil may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
Applies to verapamil: oral capsule extended release, oral capsule extended release 24 hr, oral tablet, oral tablet extended release, oral tablet extended release 24 hr
Other dosage forms:
As well as its needed effects, verapamil may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking verapamil, check with your doctor immediately:Less common
Some verapamil side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
Applies to verapamil: compounding powder, intravenous solution, oral capsule extended release, oral tablet, oral tablet extended release
Constipation due to verapamil appears to be related to a delay of colonic transit and not to an effect on upper gastrointestinal transit.[Ref]
Gastrointestinal side effects have included constipation (up to 11.7%), nausea (up to 2.7%), dyspepsia (up to 2.7%), and diarrhea (up to 2.4%). Nausea (0.9%) and abdominal discomfort (0.6%) have been reported with intravenous verapamil. Nonobstructive, paralytic ileus (reversible upon discontinuation) has been reported infrequently. Diarrhea, dry mouth, gastrointestinal distress, and gingival hyperplasia have been reported during open trials/postmarketing experience.[Ref]
Cardiovascular side effects have included hypotension (up to 2.5%), new or worsened congestive heart failure (CHF) or pulmonary edema (negative inotropism; 1.8%), bradycardia (heart rate less than 50/minute; 1.4%), atrioventricular (AV) block (first-degree; up to 1.7%), AV block (total first-, second-, and third-degree; 1.2%), AV block (second- and third-degree; 0.8%), and postural hypotension (up to 0.4%). Symptomatic hypotension (1.5%), bradycardia (1.2%), and severe tachycardia (1%) have been reported with intravenous verapamil. In studies related to control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rate less than 50/minute at rest (15%) and asymptomatic hypotension (5%) were reported. Dizziness, hypotension, peripheral edema, and headache are not uncommon and are related to vasodilation of vascular smooth muscle. Verapamil may accelerate conduction of anomalous AV conduction tissue, as in the Wolff-Parkinson-White syndrome, which can result in worsened tachycardia, including malignant ventricular tachyarrhythmias or accelerated junctional tachycardia. Because of this potentially fatal side effect, verapamil is not recommended in patients with atrial fibrillation and premature ventricular depolarizations. Angina pectoris, AV block (second- and third-degree), atrioventricular dissociation, CHF, pulmonary edema, abnormal ECG, chest pain, claudication, hypertension, myocardial infarction, palpitations, and purpura (vasculitis) have been reported during open trials/postmarketing experience.[Ref]
CHF or pulmonary edema may be particularly important in patients with poor left ventricular function.
Various conduction disturbances have been reported with verapamil therapy, including bradycardia, AV block, first-, second-, third-degree heart block, and left bundle branch block.
One study of patients with the Wolff-Parkinson-White syndrome (WPW) has shown that patients with a history of WPW complicated by atrial fibrillation and a history of reciprocating tachycardias with rapid conduction over an accessory pathway during atrial fibrillation are more susceptible to ventricular fibrillation after verapamil than those without a history of a rapid ventricular response. A small series of patients with WPW complicated by atrial fibrillation and a rapid ventricular response who developed cardiac arrest within 1 to 10 minutes after receiving intravenous verapamil has been reported.
The mechanism by which verapamil may enhance the ventricular rate response to atrial fibrillation is not known. Verapamil may directly shorten the refractory period of the accessory pathway or cause reflex tachycardia indirectly by causing peripheral vasodilation.[Ref]
A 70-year-old man with supraventricular tachycardia began to experience uncontrollable, irregular, and symmetrical jerking movements in his extremities and torsional movements in his trunk 10 months after beginning verapamil. Both myoclonic and dystonic movements occurred during activity and rest. An electroencephalogram was normal. The movements were not initiated by photic stimulation, hyperventilation, or acoustic stimuli. Once diltiazem was substituted, the movements gradually resolved over the ensuing three weeks. There was no rechallenge.
A 28-year-old woman was treated for supraventricular tachycardia with 10 mg of intravenous verapamil for 3 days in a row. After the third dose, the patient experienced involuntary movements in the buccolingual and neck muscles which made language articulation difficult. The patient also experienced episodes of compulsory neck extension and spasmodic movements of the eyes going upwards. The patient was treated with diazepam parenterally and the symptoms disappeared after 24 hours.[Ref]
Nervous system side effects have included headache (up to 12.1%), dizziness (up to 4.7%), lethargy (up to 3.2%), fatigue (up to 4.5%), sleep disturbances (up to 1.4%), paresthesia (up to 1%), and rare neurologic complaints (including paresthesias, sleeping problems, and tremors; less than 1%). Dizziness (1.2%), headache (1.2%), sleepiness, vertigo, and rare cases of seizures during injection have been reported with intravenous verapamil. Rare cases of muscle fasciculations in patients with underlying neuromuscular diseases, stroke associated with verapamil-induced hypotension, exacerbation of myasthenia gravis, and myoclonic dystonia have been reported. Cerebrovascular accident, confusion, equilibrium disorders, extrapyramidal symptoms, insomnia, paresthesia, shakiness, somnolence, syncope, and tinnitus have been reported during open trials/postmarketing experience.[Ref]
Other side effects have included flu syndrome (up to 3.7%), peripheral edema (up to 3.7%), edema (up to 3%), pain (up to 2.4%), fatigue (1.7%), accidental injury (up to 1.5%), ankle edema (up to 1.4%), and flushing (up to 0.8%). Asthenia has been reported during open trials/postmarketing experience.[Ref]
Immunologic side effects have included infection (up to 12.1%).
A 26-year-old man with rheumatic heart disease, mitral stenosis, and supraventricular tachycardia became apneic following a 5 mg intravenous bolus of verapamil. His heart rhythm at the time was supraventricular tachycardia at 290 beats per min; his blood pressure is not reported. The patient responded to assisted ventilation, oxygen, and DC cardioversion. The authors of this case report have located two other such cases, one of which had "stable hemodynamics," but died due to intravenous verapamil-associated acute respiratory arrest.
A 66-year-old woman with a 10-year history of hypertension and bronchial asthma was switched from immediate-release verapamil to sustained-release verapamil. The patient developed dyspnea, cough, and wheezing after taking the first tablet. The patient experienced similar reactions on three subsequent occasions with verapamil sustained-release administration.[Ref]
Respiratory side effects have included upper respiratory infection (up to 5.4%), pharyngitis (up to 3%), sinusitis (up to 3%), rhinitis (up to 2.7%), and dyspnea (up to 1.4%). Extremely rare cases of respiratory arrest have been associated with the use of intravenous verapamil. The mechanism is unknown. An acute asthma attack associated with sustained-release verapamil has been reported. Dyspnea has also been reported during open trials/postmarketing experience.[Ref]
Hepatic side effects have included elevated liver enzymes (up to 1.4%), and elevated transaminases with or without elevated serum bilirubin and alkaline phosphatase. The mechanism of injury is not known. Verapamil-associated hepatotoxicity is considered to be idiosyncratic, although some cases indicate a probable hypersensitivity mechanism. Elevated liver enzymes have also been reported during open trials/postmarketing experience.[Ref]
Transient increases in liver function tests may occur but generally resolve following discontinuation of verapamil, although these changes may abate even with continued administration. A hypersensitivity mechanism is suspected since some cases report eosinophilic infiltrations and moderate cholestasis on liver biopsy.
Hepatic side effects may be more likely and more severe in patients with liver disease. It is recommended that verapamil therapy be reconsidered if this patient's liver disease is severe. Monitoring liver function tests during therapy is recommended.[Ref]
Dermatologic side effects have included rash (up to 1.4%). Diaphoresis has been reported with intravenous verapamil. Arthralgia and rash, exanthema, hair loss, hyperkeratosis, macules, sweating, urticaria, Stevens-Johnson syndrome, and erythema multiforme have been reported during open trials/postmarketing experience.[Ref]
Endocrine side effects have rarely included interference with the release or synthesis of prolactin inhibitor factor in the hypothalamus; however, the mechanism is not known. A single case of hyperglycemic metabolic acidosis has been associated with sustained-release verapamil. Galactorrhea/hyperprolactinemia has been reported during open trials/postmarketing experience.[Ref]
Due to verapamil-induced hyperprolactinemia, rare cases of galactorrhea have been reported in both sexes.[Ref]
Renal side effects have included rare cases of oliguria and worsened renal function in patients with preexisting chronic renal failure.[Ref]
Rare cases of hypertensive patients with chronic renal failure who developed acute oliguric renal failure after receiving verapamil have been reported. These patients also developed symptomatic hypotension associated with slow cardiac arrhythmias.[Ref]
Genitourinary side effects have included rare cases of sexual impotence and loss of libido among males. Gynecomastia, galactorrhea/hyperprolactinemia, impotence, increased urination, and spotty menstruation have been reported during open trials/postmarketing experience.[Ref]
After the onset of impotence, one patient elected to discontinue verapamil. His impotence resolved upon drug discontinuation, and recurred upon rechallenge.[Ref]
Musculoskeletal side effects have included myalgia (up to 1.1%) and bizarre perceptual symptoms most closely described as cold extremities. Muscle fatigue has been reported with intravenous verapamil. Arthralgia (with rash) and muscle cramps have been reported during open trials/postmarketing experience.[Ref]
Three case reports have been found by one practitioner. In each case, unusual symptoms of cold extremities and paresthesias without objective evidence of a neuromuscular or cardiac etiology were described. The symptoms resolved upon discontinuation and, in each case, recurred upon drug rechallenge.[Ref]
Psychiatric side effects have included rare cases of depression. Emotional depression has been reported with intravenous verapamil. Psychotic symptoms have been reported during open trials/postmarketing experience.[Ref]
Hematologic side effects have included ecchymosis or bruising during open trials/postmarketing experience.[Ref]
Hypersensitivity side effects have included aggravated allergy during open trials/postmarketing experience. In rare cases of hypersensitivity, broncho/laryngeal spasm accompanied by itch and urticaria has been reported with intravenous verapamil.[Ref]
Ocular side effects have included blurred vision during open trials/postmarketing experience. Rotary nystagmus has been reported with intravenous verapamil.[Ref]
1. Zachariah PK, Sheps SG, Oshrain C, et al "Antihypertensive efficacy of sustained-release verapamil." J Clin Hypertens 3 (1987): 536-46
2. "Product Information. Covera-HS (verapamil)." Searle, Skokie, IL.
3. Raftos J "Verapamil in the long-term treatment of angina pectoris." Med J Aust 07/26/80 (1980): 78-80
4. Guttenberg SA "Chemical injury of the oral mucosa from verapamil." N Engl J Med 323 (1990): 615
5. Doughty JC, Donald AK, Keogh G, Cooke TG "Stercoral perforation with verapamil." Postgrad Med J 70 (1994): 525
6. Panidis IP, Morganroth J, Baessler C "Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis." Am J Cardiol 52 (1983): 1197-201
7. Davis PJ, Fagan TC, Topmiller MJ, Levine JH, Ferdinand KC "Treatment of mild hypertension with low once-daily doses of a sustained-release capsule formulation of verapamil." J Clin Pharmacol 35 (1995): 52-8
8. "Product Information. Verelan PM (verapamil)." Schwarz Pharma, Mequon, WI.
9. Brogden RN, Benfield P "Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease." Drugs 51 (1996): 792-819
10. Bursztyn M, Ghanem J, Kobrin I, Fidel J, Ben-Ishay D "Comparison of verapamil and captopril in elderly hypertensive subjects: results of a randomized, double-blind, crossover study." J Cardiovasc Pharmacol 21 (1993): 84-8
11. Steele RM, Schuna AA, Schreiber RT "Calcium antagonist-induced gingival hyperplasia." Ann Intern Med 120 (1994): 663-4
12. Baky SH, Singh BN "Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics." Pharmacotherapy 2 (1982): 328-50
13. Weiner DA, McCabe CH, Cutler SS, et al "Efficacy and safety of verapamil in patients with angina pectoris after 1 year of continuous, high-dose therapy." Am J Cardiol 51 (1983): 1251-5
14. McTavish D, Sorkin EM "Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension." Drugs 38 (1989): 19-76
15. Krevsky B, Maurer AH, Niewiarowski T, Cohen S "Effect of verapamil on human intestinal transit." Dig Dis Sci 37 (1992): 919-24
16. Pritza DR, Bierman MH, Hammeke MD "Acute toxic effects of sustained-release verapamil in chronic renal failure." Arch Intern Med 151 (1991): 2081-4
17. Zlotogorski A "Calcium blockers and gingival hyperplasia." Oral Surg Oral Med Oral Pathol Sept (1991): 316
18. Lewis GR "Long-term results with verapamil in essential hypertension and its influence on serum lipids." Am J Cardiol 57 (1986): d35-8
19. Frishman WH, Eisen G, Charlap S, Strom JA "Long-term safety and efficacy of immediate-release and sustained-release oral verapamil in systemic hypertension." J Clin Hypertens 3 (1987): 605-9
20. Mehta AV, O'Riordan AC "Verapamil-induced gingival hyperplasia in children." Am Heart J 124 (1992): 535-6
21. Benaim ME "Asystole after verapamil." Br Med J 04/15/72 (1972): 169-70
22. Echizen H, Vogelgesang B, Eichelbaum M "Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism." Clin Pharmacol Ther 38 (1985): 71-6
23. Pollak A, Falk RH "Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis." Chest 104 (1993): 618-20
24. Schwartz JB "Verapamil in atrial fibrillation: the expected, the unexpected, and the unknown." Am Heart J 106 (1983): 173-6
25. Stehle G, Buss J, Eibach J, et al "Cardiogenic shock associated with verapamil in a patient with liver cirrhosis." Lancet 336 (1990): 1079
26. Mooy J, Schols M, Baak MV, et al "Pharmacokinetics of verapamil in patients with renal failure." Eur J Clin Pharmacol 28 (1985): 405-10
27. McGovern B, Garan H, Ruskin JN "Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome." Ann Intern Med 104 (1986): 791-4
28. Hame A, Peter T, Platt M, Mandel WJ "Effects of verapamil on supraventricular tachycardia in patients with overt and concealed wolff-parkinson-white syndrome." Am Heart J 101 (1981): 600-12
29. Winters SL, Schweitzer P, Kupersmith J, Gomes JA "Verapamil-induced polymorphous ventricular tachycardia." J Am Coll Cardiol 6 (1985): 257-9
30. Shimoni A, Maorkendler Y, Neuman Y "Verapamil-induced acute right heart failure." Am Heart J 132 (1996): 193-4
31. Jacob AS, Nielsen DH, Gianelly RE "Fatal ventricular fibrillation following verapamil in Wolff-Parkinson-White syndrome with atrial fibrillation." Ann Emerg Med 14 (1985): 159-60
32. Saikawa T, Inoue K, Ohmura I, et al "The paradoxical adverse effect of verapamil for treating clinical paroxysmal supraventricular tachycardia." Jpn Heart J 28 (1987): 107-13
33. Ahmed JH, Godden J, Meredith PA, Elliott HL "R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate." Br J Clin Pharmacol 36 (1993): 93-8
34. Obel IWP "Emergency treatment of acute sustained tachyarrhythmias." S Afr Med J 85 (1995): 745-6
35. Arstall MA, Beltrame JF, Mohan P, Wuttke RD, Esterman AJ, Horowitz JD "Incidence of adverse events during treatment with verapamil for suspected acute myocardial infarction." Am J Cardiol 70 (1992): 1611-2
36. Schwartz JB, Jeang M, Raizner AE, et al "Accelerated junctional rhythms during oral verapamil therapy." Am Heart J 107 (1984): 440-3
37. Shah AR, Passalacqua BR "Case report: sustained-release verapamil overdose causing stroke: an unusual complication." Am J Med Sci 304 (1992): 357-9
38. Dhein S, Schott M, Gottwald E, Klaus W "Electrocardiological profile and proarrhythmic effects of quinidine, verapamil and their combination: a mapping study." Naunyn Schmiedebergs Arch Pharmacol 352 (1995): 94-101
39. Pahor M, Manto A, Pedone C, Carosella L, Guralnik JM, Carbonin P "Age and severe adverse drug reactions caused by nifedipine and verapamil." J Clin Epidemiol 49 (1996): 921-8
40. Hicks CB, Abraham K "Verapamil and myoclonic dystonia." Ann Intern Med 103 (1985): 154
41. Pina MA, Ara JR, Remirez A, Castiella J "Verapamil and acute dystonia." J Clin Pharm Ther 23 (1998): 79-80
42. Thomke F, Vogt T, Roder R, Hopf HC "Fasciculations due to verapamil in a patient with neuropathy." J Neurol 237 (1990): 448-9
43. Padrell MD, Navarro M, Faura CC, Horga JF "Verapamil-induced parkinsonism." Am J Med 99 (1995): 436
44. Reverte M "Adverse effect of verapamil in myasthenia gravis: an additional comment." Muscle Nerve 16 (1993): 879-81
45. Jacobsen FM, Sack DA, James SP "Delirium induced by verapamil." Am J Psychiatry 144 (1987): 248
46. Rosansky SJ "Verapamil toxicity: treatment with hemoperfusion." Ann Intern Med 114 (1991): 340-1
47. Radhakrishnan S, Talwar KK, Kaushal R, Bhatia ML "Respiratory arrest with intravenous verapamil." Am Heart J 111 (1986): 622
48. Ben-noun L "Acute asthma associated with sustained-release verapamil." Ann Pharmacother 31 (1997): 593-5
49. Guarascio P, D'Amato C, Sette P, et al "Liver damage from verapamil." Br Med J 288 (1984): 362-3
50. Stern EH, Pitchon R, King BD, Wiener I "Possible hepatitis from verapamil." N Engl J Med 306 (1982): 612-3
51. Brodsky SJ, Cutler SS, Weiner DA, Klein MD "Hepatotoxicity due to treatment with verapamil." Ann Intern Med 94 (1981): 490-1
52. Kumar KL, Colley CA "Verapamil-induced hepatotoxicity." West J Med 160 (1994): 485-6
53. Nash DT, Feer TD "Hepatic injury possibly induced by verapamil." JAMA 249 (1983): 395-6
54. Hare DL, Horowitz JD "Verapamil hepatotoxicity: a hypersensitivity reaction." Am Heart J 111 (1986): 610-11
55. Fearrington EL, Rand CH, Rose JD "Hyperprolactinemia-galactorrhea induced by verapamil." Am J Cardiol 51 (1983): 1466-7
56. Peer G, Korzets A, Levtov O "Plasma lipid profile in verapamil-treated hypertensive patients." Int J Clin Pharmacol Ther Toxicol 25 (1987): 489-92
57. Gluskin LE, Strasberg B, Shah JH "Verapamil-induced hyperprolactinemia and galactorrhea." Ann Intern Med 95 (1981): 66-7
58. Dombrowski RC, Romeo JH, Aron DC "Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma." Ann Pharmacother 29 (1995): 999-1001
59. Thomas SH, Stone CK, May WA "Exacerbation of verapamil-induced hyperglycemia with glucagon." Am J Emerg Med 13 (1995): 27-9
60. Romeo JH, Dombrowski R, Kwak YS, Fuehrer S, Aron DC "Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men." Clin Endocrinol (Oxf) 45 (1996): 571-5
61. Vazquez C, Huelmos A, Alegria E, Errasti P, Purroy A "Verapamil deleterious effects in chronic renal failure." Nephron 72 (1996): 461-4
62. King BD, Pitchon R, Stern EH, et al "Impotence during therapy with verapamil." Arch Intern Med 143 (1983): 1248-9
63. Kumana CR, Mahon WA "Bizarre perceptual disorder of extremities in patients taking verapamil." Lancet 06/13/81 (1981): 1324-5
64. Dassylva B "Verapamil may cause depression." Can J Psychiatry 38 (1993): 299-300
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.